10.08.2018
Carl Zeiss Meditec AG DE0005313704
DGAP-News: Carl Zeiss Meditec accelerates growth
DGAP-News: Carl Zeiss Meditec AG / Key word(s): 9-month figures
Carl Zeiss Meditec accelerates growth
10.08.2018 / 06:55
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Carl Zeiss Meditec accelerates growth
Positive contributions from both strategic business units and from all
regions
JENA, 10 August 2018
After nine months 2017/18, Carl Zeiss Meditec AG was able to achieve further
encouraging growth in all strategic business units and regions: Revenue
increased by 7.1 percent (adjusted for currency effects, 11.7 percent), to
EUR926.3m (prior year: EUR864.7m). Earnings before interest and taxes (EBIT)
rose slightly, to EUR134.8m (prior year: EUR132.6m). The adjusted EBIT
margin remained stable at 14.8 percent (prior year: 14.7 percent). Earnings
per share reached EUR0.92 (prior year: EUR1.10).
"As already announced in early July, given the positive revenue growth in
the third quarter, the revenue forecast for fiscal year 2017/18 was
increased slightly to EUR1,250m - EUR1,300m. I am particularly pleased that
both Strategic Business Units and all regions once again contributed
significantly to this. The positive development of our latest product
innovations validates our strategy to further drive forward the development
of innovative solutions in the medical sector and to further expand our
global orientation," said Dr. Ludwin Monz, President and CEO of Carl Zeiss
Meditec AG, commenting on the result.
Solid growth in both strategic business units
The Ophthalmic Devices strategic business unit (SBU) increased its revenue
by 6.4 percent in the first nine months of the current fiscal year (adjusted
for currency effects: 10.7 percent), to EUR681.0m, compared with EUR639.9m
in the same period of the prior year. The laser systems business for
refractive vision correction and diagnostic instruments developed
particularly well. There was also continued solid demand for intraocular
lenses for the treatment of cataracts.
Revenue in the Microsurgery SBU grew by 9.1 percent (adjusted for currency
effects: 14.3 percent). Revenue from surgical microscopes and visualization
solutions climbed to EUR245.2m, compared with EUR224.8m in the prior year.
This was particularly due to the new KINEVO 900 visualization system for
neurosurgeons.
Strong organic growth in all regions
Revenue in the EMEA region increased by 8.6 percent (adjusted for currency
effects: 10.0 percent) to almost EUR282.0m (prior year: EUR259.6m). This
increase was attributable to the stable development in the core markets
Germany and France, and to solid growth in the UK and Southern Europe.
On a currency adjusted basis, revenue in the Americas region grew by 11.7
percent to EUR279.3m (prior year: EUR272.5m). Due to negative currency
effects, reported revenue only grew slightly by 2.5 percent year-on-year.
The positive trend in the US market continued.
The Asia/Pacific region (APAC) grew by 9.7 percent, to EUR364.9m (prior
year: EUR332.6m). After adjustment for currency effects, this corresponds to
an increase of 13.0 percent. The largest contributions to growth came from
China and South Korea.
Earnings per share declined to EUR0.92 (prior year: EUR1.10). It was,
however, predominantly non-operating factors that contributed to this,
specifically the one-time proceeds from the sale of non-strategic assets in
the prior year, a negative currency result and the increase in the number of
outstanding shares following the capital increase in March 2017.
Carl Zeiss Meditec confirms its revenue projections for fiscal year 2017/18
as published in the ad hoc disclosure dated 3 July 2018. Revenue is expected
to be within the range of EUR1,250m - EUR1,300m (previously: EUR1,230m -
EUR1,280m). The EBIT margin is expected to remain within the range of 14
percent to 16 percent on an adjusted basis.
Revenue by strategic business unit
All 9 months 9 months Change from Change from prior year
figures 2017/18 2016/17 prior year (adjusted for currency
in EURm effects)
Ophthalmi- 681.0 639.9 +6.4% +10.7%
c Devices
Microsurg- 245.2 224.8 +9.1% +14.3%
ery
Total 926.3 864.7 +7.1% +11.7%
Revenue by region
All 9 months 9 months Change from Change from prior year
figures 2017/18 2016/17 prior year (adjusted for currency
in EURm effects)
EMEA 282.0 259.6 +8.6% +10.0%
Americas 279.3 272.5 +2.5% +11.7%
APAC 364.9 332.6 +9.7% +13.0%
Total 926.3 864.7 +7.1% +11.7%
Contact for investors and press
Sebastian Frericks
Director Investor Relations Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: [email protected]
www.zeiss.com/press
---------------------------------------------------------------------------
10.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
712919 10.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Carl Zeiss Meditec AG ISIN: DE0005313704 können Sie bei EQS abrufen
Medtech , 531370 , AFX , XETR:AFX